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Abstract
Background: Humoral hypercalcemia of malignancy is rarely associated with cholangiocarcinoma
(CC).
Case report: A 77-year-old man was admitted with confusion. Computer tomography showed a
large multinodular mass in the right lobe of the liver and smaller lesions in the right lung. Liver
histology confirmed the diagnosis of CC. Elevated calcium levels and suppressed intact parathyroid
hormone in the absence of skeletal metastases or parathyroid gland pathology suggested the
diagnosis of humoral hypercalcemia of malignancy (HHM). Treatment of hypercalcemia with saline
infusion, loop diuretics, biphosphonate and calcitonin was effective in normalizing calcium levels and
consciousness state within 48 hours, but a relapse occurred 4 weeks later and the patient
succumbed to his disease.
Conclusion: Clinicians should be aware of this rare manifestation of CC as prompt and aggressive
correction of hypercalcemia alleviates symptoms and improves patient's quality of life, despite the
poor overall prognosis.
Background
Hypercalcemia occurs in around 30% of patients with
malignant disease. It is caused either by tumor production
of humoral factors [humoral hypercalcemia of malig-
nancy (HHM)] or by locally enhanced bone resorption
associated with metastatic lesions of solid cancers [1].
Cholangiocarcinoma (CC) is an epithelial tumor of the
biliary tree that accounts for 10 to 15% of all hepatobil-
iary malignancies. It represents 3% of gastrointestinal
tract cancers and its incidence is increased worldwide [2].
The majority of patients with CC are older than 65 years
of age and although cases of long-term survival have been
reported after resection, most patients with unresectable
disease die between 6 months and 1 year following diag-
nosis [3]. HHM has been rarely documented in patients
with CC. In this report, we present a case of advanced CC
associated with clinical and laboratory findings consistent
with HHM.
Case presentation
A 77-year-old Caucasian man with a history of type II dia-
betes and hypertension presented with confusion. Other
symptoms included general fatigue, anorexia, weight loss,
nausea and occasional vomiting that extended over a
period of 2 months. He was afebrile and physical exami-
nation revealed an enlarged non-tender liver with an
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irregular border. Blood tests showed a white blood cell
count of 14470 K/μl, Neu 82%, urea 100 mg/dl (normal
range, 17-50), creatinine 1.4 mg/dl (normal range, 0.7-
1.4), calcium 12.6 mg/dl (normal range, 8.6-10.2), phos-
phorus 2.9 mg/dl (normal range, 2.7-4.5), albumin 3.6 g/
dl (normal range, 3.5-5.5), aspartate aminotransferase
(SGOT) 77 U/L (normal range, 5-40), alanine ami-
notransferase (SGPT) 49 U/L (normal range, 5-40), alka-
line phosphatase (ALP) 563 U/L (normal range, 64-280),
gamma-glutamyl transferase (γGT) 500 U/L (normal
range, 11-49), and plasma ammonia 44 μg/dl (normal
range, < 75). The rest of blood routine biochemistry was
unremarkable. Parathyroid hormone (PTH) was sup-
pressed at 1.55 pg/dl (normal range, 8-76) and carci-
noembryonic antigen 19-9 (CA 19-9) was elevated at 223
U/ml (normal range, <37). Computer tomography (CT)
revealed a large multinodular mass in the right lobe of the
liver consistent with neoplastic disease (Figure 1) and
smaller nodules in the right lung. Brain CT was normal,
bone scan with 99mTc-MDP showed no evidence of meta-
static bone disease, and parathyroid scan with 99mTc-MIBI
double phase was unremarkable. A liver surgical biopsy
confirmed the diagnosis of CC (Figure 2). Neoplastic cells
stained positively for cytokeratin 7 and 19.
The patient was treated with intravenous hydration, furo-
semide, ibandronate, and calcitonin, with calcium levels
and consciousness state normalizing within 48 hours. He
declined chemotherapy and was discharged home, from
where he was readmitted 4 weeks later with relapsed
hypercalcemia and progressively worsening confusion. A
repeat CT scan showed significant expansion of the liver
mass. Treatment of hypercalcemia resulted again in rapid
restoration of his consciousness level. However, overall
prognosis was poor and the patient died due to progres-
sive disease within 3 months of diagnosis.
Discussion
HHM is typically associated with squamous cell carcino-
mas of head and neck, esophagus and lung. Other tumors
commonly associated with HHM include breast, renal,
bladder and ovarian cancers, human T-cell lymphotropic
virus-1 lymphoma, and some endocrine tumors. It is
rarely seen in association with colon adenocarcinoma,
gastric carcinoma, small cell carcinoma, and prostate can-
cer. HHM is characterized biochemically by elevated
serum calcium, low serum phosphorous, low PTH, low
1,25 (OH)2 vitamin D levels and elevated nephrogenous
cyclic AMP excretion rate [4].
CC is rarely associated with HHM. A retrospective analysis
of 190 CC cases with hypecalcemia by Oldenburg et al.
showed that in 17.5% of those cases hypercalcaemia was
not associated with metastatic bone disease, while 5
patients had serum immunoreactive PTH levels consistent
with ectopic hyperparathyroidism [5]. Since then, a few
case reports in the english literature have linked CC with
HHM [6-10].
Many factors including vascular endothelial growth factor
(VEGF) and interleukin -8 and -11 have been implicated
Computer tomography image of the abdomen showing a lob- ulated mass in the right lobe of the liver Figure 1
Computer tomography image of the abdomen show-
ing a lobulated mass in the right lobe of the liver.
Arborizing tubular structures lined by columnar neoplastic  cells within dense collagenous stroma Figure 2
Arborizing tubular structures lined by columnar neo-
plastic cells within dense collagenous stroma. (H&E 
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in promoting HHM, although currently, parathyroid hor-
mone-related protein (PTH-rP) is believed to be the major
mediator [11]. Circulating levels of PTH-rP are elevated in
80% of patients with HHM [4]. PTH-rP shares many struc-
tural features with PTH and both share the same PTH
receptor [12,13]. Similarly to PTH, PTH-rP interacts with
the PTH/PTH-rP receptor that mediates the renal tubular
reabsorption of calcium and stimulates osteoclastic bone
resorption resulting in hypercalcemia [14]. Hence, medi-
cal treatment of HHM should include hydration by saline
infusion, loop diuretics to promote urinary calcium excre-
tion, and antiresorptives such as calcitonin and biphos-
phonates [15].
Conclusion
We presented a case of advanced CC associated with
symptomatic hypercalcemia. Increased calcium levels and
suppressed intact PTH levels, in the absence of metastatic
bone disease and parathyroid gland pathology, suggested
the diagnosis of HHM. Clinicians should be aware of this
rare manifestation of CC since prompt correction of
hypercalcemia affords symptomatic relief and improves
the quality of life of patients.
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